Q3 2024 Earnings Call Transcript October 30, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $3, expectations ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Background: Therapeutic options for patients with treatment-resistant schizophrenia are limited, and combination treatment with atypical antipsychotic drugs is an often used strategy. We tested ...

Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.

serotonergic and adrenergic receptors – failed to improve the positive and negative schizophrenia symptom scale (PANSS) compared to conventional therapy in patients with treatment-resistant ...

The stabilization phase covers the first 6 months or more after the onset of an acute phase, during which acute psychotic symptoms decrease in severity. The treatment goals during the ...

Discover how metabolic ketogenic therapy differs from the popular diet trend and its potential benefits for bipolar disorder.

Specific subtypes and transmission clusters for HIV could require targeted interventions to control spread of HIV that is ...

The treatment guidelines for schizophrenia recommend tailored psychosocial intervention therapies. However, access to such interventions is limited. Therefore, it is proposed that, by providing ...

Good morning, and thank you for standing by. Welcome to the AbbVie third quarter 2024 earnings conference call. (Operator Instructions) Today's call is being recorded. I would now like to introduce Ms ...

Schizophrenia is a severe and debilitating psychiatric disorder that involves psychotic symptoms such as hallucinations and delusions, accompanied with regressive behaviour.